REVEAL HPS-3 TIMI-55 trial

Revision as of 18:09, 18 August 2014 by Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}}; {{AE}} {{Rim}} ==Official Title== ==Objective== ==Sponsor== ==Timeline== {| class="wikitable" border="1" style="backgro...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

REVEAL HPS-3 TIMI-55 trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of REVEAL HPS-3 TIMI-55 trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on REVEAL HPS-3 TIMI-55 trial

CDC on REVEAL HPS-3 TIMI-55 trial

REVEAL HPS-3 TIMI-55 trial in the news

Blogs on REVEAL HPS-3 TIMI-55 trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for REVEAL HPS-3 TIMI-55 trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Objective

Timeline

Timeline
Start Date
End Date
Status

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT01252953.

Study Description

Study Description
Study Type
Study Phase
Study Design
Allocation
Endpoint
Interventional Model
Masking
Study Details
Primary Purpose
Condition
Intervention
Study Arms
Population Size

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT01252953.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcomes

Primary Outcomes

Publications

Results

Conclusion

Pending

References